SARS-CoV-2 immunodominant epitopes identified as vaccine candidates
Researchers have analysed the SARS-CoV-2 proteome to reveal seven promising immunodominant epitopes that could aid in the development of a COVID-19 vaccine.
List view / Grid view
Researchers have analysed the SARS-CoV-2 proteome to reveal seven promising immunodominant epitopes that could aid in the development of a COVID-19 vaccine.
Best practices and optimised protocols with Precellys for high throughput sample preparation related to virus studies.
Dr Jing Watnick discusses how lessons learnt from cancer immunotherapy treatments could be applied to the development of COVID-19 therapies.
Researchers reveal the main protease (Mpro) of SARS-CoV-2 is highly sensitive to disruption, therefore Mpro inhibitors could be a potential COVID-19 therapeutic.
Scientists reveal their reliable and tuneable simulator created using swine lungs, synthetic actuators and artificial muscles.
A result is only as good as the sample preparation that preceded it.
ESHG 2019: Automated sample preparation using magnetic bead technology and KingFisher instruments.
The team found that the expression of the APOE4 gene variant in pericytes caused amyloid plaque formation in a blood-brain barrier model.
Automated detection and isolation of pathogens for multiple samples types.
New opportunities for liquid biopsy: At automated workflow for isolating circulating tumor cells using KingFisher instruments.
The team found microglia and CD8 T cells were vital to protecting neurons from vesicular stomatitis virus (VSV) infection and suggest loss of taste and smell in COVID-19 could be due to a certain mechanism of infection.
A simple and sensitive method for nucleic acid extraction from virus-containing samples, with a range of viral loads.
Isolate high-quality, inhibitor-free DNA and RNA from human stool and other sample types suitable for metagenomics sequencing.
Experts suggest that increasing biological and conditional variations in their experiments could not only make them more reproducible but also reduce the total number of animals required.
Arsalan Azimi explains why inhibiting TMPRSS2 with clinically proven protease blockers could work as a therapeutic strategy against COVID-19.